ZM

Zahra Mahmoudjafari

Mutual Connections
Loading...
S9-052025-1213901

Send Message

No file chosen
1 Publications
0 Followers
0 Following
0 Questions

👤 About

Skills & Expertise

No skills added yet.

Research Interests

No research interests added yet.

Connect With Me

📚 Publications (1)

Journal: Leukemia & Lymphoma • April 2025
Fixed-treatment duration glofitamab and treat-to-progression epcoritamab are approved in the US for diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies. An economic model was developed to e...
Relapsed/refractory Dlbcl Cost analysis Epcoritamab Bispecifics Glofitamab
dd